



Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 4<sup>th</sup> October 2019  
Ein Cyf / Our Ref: 19-I-012

☎ 01639 648363  
✉ FOIA.Requests@wales.nhs.uk

[Redacted]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 12<sup>th</sup> September 2019. Your request sought information relating to multiple myeloma and chronic lymphocytic leukaemia.

**1. Does your health board treat adult multiple myeloma [MM]? - if you refer your multiple myeloma patients to another centre, please state which.**

Yes

**2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;**

<b>Bortezomib [Velcade]</b>	<5
<b>Carfilzomib [Kyprolis]</b>	Nil
<b>Ixazomib [Ninlaro]</b>	Nil
<b>Lenalidomide [Revlimid]</b>	23
<b>Daratumumab [Darzalex]</b>	10
<b>Melphalan, prednisolone and thalidomide (known as MPT)</b>	Nil
<b>Cyclophosphamide, thalidomide and dexamethasone (known as CTD)</b>	<5
<b>Pomalidomide [Imnovid]</b>	18

**3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?**

24 with SACT

**If possible, how many CLL patients treated were new to therapy in the past 3 months?**



**4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;**

<b>Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)</b>	<5
<b>Bendamustine and rituximab (known as BR)</b>	<5
<b>Ibrutinib [Imbruvica]</b>	<5
<b>Chlorambucil</b>	<5
<b>Venetoclax</b>	<5
<b>Obinutuzumab</b>	<5
<b>Idelalisib</b>	<5
<b>Fludarabine and rituximab (known as FR)</b>	Nil
<b>High-dose prednisone and rituximab</b>	Nil
<b>Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)</b>	Nil
<b>Alemtuzumab (Campath) with rituximab</b>	Nil

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely

*P. a. wenger*

Pam Wenger  
**Director of Corporate Governance**

